Bortezomib for the treatment of multiple myeloma
K Scott, PJ Hayden, A Will… - Cochrane Database of …, 2016 - cochranelibrary.com
Background Multiple myeloma is a malignancy of plasma cells accounting for approximately
1% of cancers and 12% of haematological malignancies. The first‐in‐class proteasome …
1% of cancers and 12% of haematological malignancies. The first‐in‐class proteasome …
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta …
Cochrane Haematology Group… - Cochrane Database …, 1996 - cochranelibrary.com
Background Multiple myeloma is a bone marrow‐based hematological malignancy
accounting for approximately two per cent of cancers. First‐line treatment for transplant …
accounting for approximately two per cent of cancers. First‐line treatment for transplant …
Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: a systematic review and network meta-analysis of 14,533 patients over 29 …
L Sekine, PK Ziegelmann, D Manica… - Critical reviews in …, 2019 - Elsevier
Choice of treatment for newly diagnosed transplant-ineligible multiple myeloma poses a
difficult task due to an ever-increasing plethora of different regimens. Attempting to clarify …
difficult task due to an ever-increasing plethora of different regimens. Attempting to clarify …
Bortezomib for the treatment of previously untreated multiple myeloma
A Romano, C Conticello, F Di Raimondo - Immunotherapy, 2013 - Taylor & Francis
Management of multiple myeloma (MM) has been drastically changed in the last 10 years
thanks to the introduction of novel agents, which, combined with the backbone of classical …
thanks to the introduction of novel agents, which, combined with the backbone of classical …
[图书][B] Chemotherapy-Induced Neuropathic Pain
RB Raffa, R Langford, JV Pergolizzi Jr, F Porreca… - 2012 - books.google.com
There have been tremendous recent advances in the pharmacotherapy, dose regimens, and
combinations used to treat cancer and for the treatment or prevention of the spread of …
combinations used to treat cancer and for the treatment or prevention of the spread of …
The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part I: B7-H1 (PD-L1) and B7-DC (PD-L2)
A Starzyńska, A Sejda, Ł Adamski, P Adamska… - … in Dermatology and …, 2022 - termedia.pl
The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part I: B7-H1
(PD-L1) and B7-DC (PD-L2) Page 1 Advances in Dermatology and Allergology 2, April/2022 …
(PD-L1) and B7-DC (PD-L2) Page 1 Advances in Dermatology and Allergology 2, April/2022 …
Endoplasmic Reticulum Stress and Emerging Therapeutic Targets in Cancer
Endoplasmic reticulum stress (ER stress) is characterized by the accumulation of misfolded
and unfolded proteins in the ER lumen. To mitigate the imbalanced ER protein-folding …
and unfolded proteins in the ER lumen. To mitigate the imbalanced ER protein-folding …
[PDF][PDF] 硼替佐米为基础的化疗方案治疗30 例老年多发性骨髓瘤临床分析
陈浩宇， 禹文君， 屈晓燕， 许家仁， 陈丽娟 - 实用老年医学, 2014 - sylnyx.com
瘤, 迄今为止仍是一种不可治愈的疾病. 在过去的10 多年中, 硼替佐米的应用明显提高了MM
治疗疗效, 其主要不良反应为外周神经病变, 带状疱疹和胃肠道反应等[1⁃ 2] …
治疗疗效, 其主要不良反应为外周神经病变, 带状疱疹和胃肠道反应等[1⁃ 2] …